|Publication number||US3717708 A|
|Publication date||Feb 20, 1973|
|Filing date||Oct 24, 1968|
|Priority date||Oct 24, 1968|
|Also published as||CA920948A1|
|Publication number||US 3717708 A, US 3717708A, US-A-3717708, US3717708 A, US3717708A|
|Inventors||S Wada, M Mozen|
|Original Assignee||Cutter Lab|
|Export Citation||BiBTeX, EndNote, RefMan|
|Non-Patent Citations (6), Referenced by (23), Classifications (11)|
|External Links: USPTO, USPTO Assignment, Espacenet|
United States Patent 1 Wada et al.
[ 1 Feb. 20, 1973  BLOOD COAGULATION COMPLEX  Assignee: Cutter Laboratories, Inc., Berkeley,
22 Filed: Oct. 24, 1968  Appl. No.: 770,424
 US. Cl ..424/l77, 260/112  Int. Cl. ..A6lk 25/00 [5 8] Field of Search ..424/177  I References Cited OTHER PUBLICATIONS Chemical Abstracts, Vol. 66, entry 9221p, 1967 citing Steinbuch et al., Probl. Gematol. Pereliv. Krovi 11(10), 15-21(1966) Lewis, Proc. Soc. for Experimental Biology and Medicine, Vol. 116, No. 1, pages 120-122, May 1964 Voss, I-Ioppe-Seylers Z. Physiol. Chem., Vol. 348, pages 1172-1178, Sept. 1967 Biggs et al., Human Blood Coagulation and its Disorders, 3rd ed., published by Blackwell Scientific Publications, Oxford, 1962, pages 208, 210, 373, & 374 Prydz, J. Clin. & Lab. Investigation, Vol. 1, pages 101-107, 1964 Melin, Studies in the Application of Chromatographic Methods for the Fractionation of the Proteins of Human Plasma, Harvard Univ. April 1964, page 43 Primary Examiner-Richard L. Huff Attorney-Bertram Bradley [5 7 ABSTRACT A lyophilized mixture of coagulation components of human origin useful in the treatment of patients, who bleed due to a congenital or acquired deficiency of one or more of the coagulation Factors [1, VII, IX, X, prepared from human plasma collected in a citrate anticoagulant, free of heparin, free of thrombin, free of the activated form of Factor X, free of depressor activity, free of anti-complement activity, and comprising the coagulation components Factors II, VII, IX, X in essentially the same proportions as normal human plasma and of a potency equivalent to a specific activity of more than 0.5 clinical unit of each component per milligram of protein; and the process of preparing such product by selective adsorption and selective fractional elution.
7 Claims, No Drawings 2 played by Factor IX, as well as by Factors II, VII and X, is illustrated by the following simplified diagram of the coagulation process.
1 BLOOD COAGULATION COMPLEX This invention relates to blood coagulation components and in general has for its object the provision of a purified composition of therapeutically useful blood coagulation components and to a method for producing such components from readily available materials.
There are estimated to be 100,000 cases of congenital hemophilia in the United States. Of these, approximately 20,000 are cases of hemophilia B, the blood of such patients being either totally devoid of plasma thromboplastin component or seriously deficient in plasma thromboplastin component. The dis-- case therefore exists in varying degrees of severity, with a sodium chloride-sodium citrate buffer, and requiring py anywhere from every Week up to further purified by cold ethanol fractionation. This. Once or twice a y The completely deficient cases preparation was used clinically with excellent results require replacement therapy once every week; the par- [Aggeler p et l T 6 h Congress, Internat. tially deficient cases require therapy only when bleeds HematoL Grune & S u N, Y,, pgs. 490-497 mg episodes occur, which may be as Seldom as Once a (1958)]. The process was later published in detail, and
year. The bleeding episodes in congenital, partiallydeficient cases are generally caused by a temporarily acquired susceptibility rather than by injury alone. Intravenous injection of a sufficiently large amount of fresh plasma, or an equivalent amount of fresh blood, temporarily corrects the defect of a deficient subject. The beneficial effect often lasts for two or three weeks, although the coagulation defect as measured by in-vitro tests on the patients blood appears improved for only two or three days. Such therapy with fresh plasma or fresh blood is effective but it has several serious drawbacks: (I) it requires ready availability of a large amount of fresh plasma; (2) requires hospitalization for the administration of the plasma; (3) a great many of the patients become sensitized to repeated blood or plasma infusions and ultimately encounter fatal transfusion reactions; (4) at best plasma can only partially alleviate the deficiency; and (5) prolonged treatment or surgery is not possible because the large amounts of blood or plasma which are required will cause acute and fatal edema.
Several investigators noted that the mixing of blood of certain hemophilic patients would result in the mutual correction of the clotting defect of each blood. Interpretation of these findings was eventually made by Aggeler and (go-workers [Proc. Soc. Exptl. Biol. Med. 79:692-696 (1952)] and S. G. White et al [Blood 8:101-124 (1953)]. These workers, studying a male patient with a severe hemorrahagic diathesis associated with a prolonged clotting time which was clinically indistinguishable from classic hemophilia, postulated the existence of a new clotting factor. Aggeler et al, recognizing that the new factor was a precursor of thromboplastin, named it Plasma Thromboplastin Component (PTC). The work was confirmed by Biggs et al. [Brit. Med. J. 2:1378-1382 (1952)] in England, who gave it the name Christmas Factor, and by Soulier and Larrieu [New Eng. J. Med. 249:547-553 (1953)] in France, who called it Antihemophilic Factor B. This factor is now officially designated Factor IX. The role Step 1 Fibrinogvn Thrombin i In collaboration with Aggeler et al., the first fractionated PTC preparation was prepared [Revue dHematologie 9:447-453 (1954)]. The PTC was absorbed .on barium sulfate from a solution of Cohn Fraction IV and eluted with 0.34 M sodium citrate. The yields are very small, and the post-infusion in-vivo activity was only about one-fourth that predicted from in-vitro assays by a prothrombin consumption test.
Later, in collaboration with Aggeler et al., a process was developed by which PTC was adsorbed onto barium sulfate from EDTA anticoagulated plasma, eluted it was pointed out that the process was never commercialized because the Albumin and Plasma Protein Fraction obtained as by-products were contaminated with potentially hazardous levels of barium [I-Iink, J. H. and Johnson, F. F., The Hemophilias, CH. 18, page 156, edited by Brinkhous, Univ. Of North Carolina Press (1964)]. Biggs et al. in England [Brit. J. Haematol.
7:349-364 (1961)] and Janiak and Soulier [Thromb. et
Diath. l-laemorr. 82406-424 (1962)] in France later Tullis et al. [New Eng. J. Med. 273:667-674 (1965)] have prepared and studied a somewhat similar plasma fraction, which they refer to as prothrombin complex. In the Tullis process, the blood was collected through a calcium-removing ion exchange resin, and the resulting resin-plasma adsorbed onto DEAE cellulose. Elution was accomplished with a sodium phosphate-sodium chloride buffer stabilized with EDTA. Clinical studies on the prothrombin complex" are described in the reference, but other data'characterizing the complex are not available.
The preponderance of blood generally taken and available for transfusion is protected from coagulation by treatment with a citrate anticoagulant which allows the blood to be utilized for only a limited period of time. After this limited time expires, this blood must be discarded or it can be made available for fractionation into certain useful components. As a matter of fact, the major source of whole blood converted to plasma for fractionation comes from outdated blood which has been protected by citrate anticoagulation. It is, therefore, important that processes for the fractionation of plasma, such as to obtain a Factor IX containing concentrate, be directed to citrate preserved blood. An object of this invention is that the process for making the concentrate of this invention starts with plasma taken from citrate preserved blood.
It is also important that such concentrates do not contain thrombin since the injection of thrombin into a human would be considered 7 dah'geiiis.
Although it is possible to neutralize thrombin activity with heparin, it would be preferable not to-have the thrombin there in the first place. Heparin is undesirable in a Factor IX containing concentrate because it also is potentially hazardous to the patient and because it causes difficulties in assaying the coagulation factors in the concentrate. In the administration of a Factor IX containing concentrate, constant monitoring of the patients coagulation status is required, and the presence of heparin will not only complicate this testing procedure, but will make the results thus obtained unreliable. An object of this invention is that the concentrate be free of both thrombin and of heparin.
It is a further object of this invention to provide a concentrate that comprises coagulation components ll, VII, IX and X in proportions essentially equal to those found in plasma, yet free of the activated form of Factor X, thereby reducing the danger of precipitating intravascular coagulation.
It is a further object of this invention to provide a,
concentrate free of the anticomplement activity which is so often associated with plasma globulins and which would make the intravenous administration of the product highly dangerous.
It is a further object of this invention to provide a very pure product by selective adsorption of active components and further selectivity by fractional elution.
Other objects and advantages of the invention will appear from the following description of preferred embodiments thereof.
Details of Making Product Very generally, the product is made by starting from Effluent I, prepared by the Cohn Method 6. The cornplex of Factors II, Vll, IX, X is adsorbed onto DEAE Sephadex, which is an anion exchanger, diethylaminoethyl Sephadex, consisting of cross-linked dextran chains with diethylaminoethyl groups attached by ether' linkages to the glucose units of the polysaccharide chains, supplied by Pharmacia Fine Chemicals, Inc., Piscataway, New Market, N. .I. The spent Effluent I is returned to the plasma fractionation process so that none of the otherplasma components 'are wasted. The DEAE Sephadex is fractionally eluted with increasing concentrations of ammonium bicarbonate solution. The complex of the invention is eluted in the fraction between 0.3 M and 0.75 M ammonium bicarbonate at pH 7.3-8.2.
More specifically, the preferred procedure is as follows:
A. Adsorb the Effluent I of the standard plasma fractionation process onto a column of freshly equilibrated DEAE Sephadex in an amount of 10 Gms. (wet weight). per liter of Effluent I, at 0 to 3C. Return the spent: Effluent I to the plasma fractionation process just prior to precipitation of Fraction n+m. B. Wash the DEAE Sephadex column with 0.2 M ammonium bicarbonate at pH 7.0-7.8 until no-further protein is eluted and discard the wash.
C. In the same manner, wash the DEAE Sephadex column with 0.3 M ammonium bicarbonate, at pH 7.07.8 until no further protein is eluted; the blue ceruloplasmin is eluted with this wash; discard the wash.
D. In the same manner, elute the DEAE Sephadex column with 0.75 M ammonium bicarbonate, at pH 7.6-7.8 until the Factor IX is eluted.
E. Freeze and lyophilize the eluate of step D; the ammonium bicarbonate sublimes leaving a salt-free protein powder equivalent to about 350 mg. per liter of Effluent I; assay for Factor IX, and store in a moistureproof container at 5c or below.
A modification of the product of this invention is the product in an electrolyte buffer suitable for intravenous administration as follows:
F. Slowly dissolve the dry protein powder in a diluent of 0.05 M sodium citrate and 0.088 M sodium chloride to result in a final concentration of 25 units of Factor IX per ml.; as the powder'dissolves, maintain the pH at -75 by additions of 1 N sodium hydroxide; adjust the final pH to 7.3 i 0.1.
G. Sterilize by filtration through a sterile 0.2 micron porosity membrane filter.
H. Aseptically fill convenient portions into sterile bottles, freeze, and lyophilize. Store at 5C.
I. For human administration, the content of the vial in step H is aseptically redissolved in water for injection. Alternatively, the product of step D can be sterile filled and lyophilized to a salt-free product. In this instance it is reconstituted with a suitable isotonic diluent prior to human injection.
The above process recites the details which are preferred at this time. However, many variations can be made without departing from the general principles of the invention.
For example, the amount of DEAE Sephadex relative to the volume of Effluent I may be varied over a wide range. The use of larger amounts of DEAE Sephadex will result in a lower degree of purity and greater yield of the coagulation complex, and a greater loss of other plasma proteins normally recoverable in subsequent steps. The use of smaller amounts of DEAE Sephadex will result in even higher degrees of purity, but will also result in considerably lower yields. Although DEAE Sephadex is the preferred anionic exchanger, presumably other anionic adsorbents would work also.
The elution step with ammonium bicarbonate is extremely important to the invention of this process. The unique selectivity obtained by application of the ammonium bicarbonate salt gradient elution combined with the unique volatility factor of ammonium bicarbonate are very important aspects of this process for the following reasons:
1. Ammonium bicarbonate being a volatile, inorganic saltis completely removed from the desiccated product thus resulting in a completely salt-free protein preparation. This offers an advantage in that the final clinical preparation may be easily adjusted to isotonicity.
2. The recovery of a salt-free protein obviates the necessity of extensive salt removal procedures such as dialysis, gel filtration, ultra filtration, etc., thus a commercially feasible large scale operation becomes more practical.
3. Ammonium bicarbonate was found to offer selectivity in the elution of the bound proteins, allowing the ready separation of undesirable impurities such as The dissolving of the dried protein, its concentration,
the nature of the electrolyte buffer, and the filtration are all standard steps which can be varied by anyone familiar with the art.
CHARACTER OF PRODUCT which contains 0.7 unit per ml. upon reconstitution.
ASSAYS In-Vito Assay of Factor IX Activity The assay was based on the partial thromboplastin time technic of Langdell, Wagner, and Brinkhous [J. Lab. Clin. Med. 41:637-647 (1953)] and the kaolin clotting time method of Proctor and Rapaport [Am. J. Clin. Path. 36:212-219 (1961)]. Platelet Factor 3 was supplied by a cephalin suspension. Maximum surface contact activation was achieved with a Celite powder. All other clotting factors (except Factor IX) were supplied by a substrate comprising plasma from a patient severely deficient in Factor IX mixed with barium sulfate adsorbed beef plasma. Quantitation of an unknown specimen was made by comparing its clotting time in the test with that achieved by dilutions of a normal standard.
REAGENTS 1. Calcium Chloride Solution. 0.05 M CaCl 2. Veronal Buffer 2.94 gm Sodium Barbital 3.67 gm. Sodium Chloride 105 ml. 0.1 N Hydrochloric Acid q.s. 500 ml. with distilled water 3. Celite. Analytical Filter Aid, Johns Manville. 4. Cephalin Suspension. Prepared from rabbit brain thromboplastin according to Bell and Alton [Nature 174:880-881 (1954)].470 5. Cephalin-Celite Reagent. Equal volumes of Cephalin Suspension diluted 1:50 in Veronal buffer at pH 7.3 i 0.1, and Celite, 1.0 gm. suspended in 5 ml. 0.9 percent NaCl solution were mixed. 6. Diluting Fluid I (DF I) 50 ml. 0.1 M Sodium Citrate 300 ml. 0. M Sodium Chloride 7. Diluting Fluid 11 (DF 11) ml. Veronal Buffer 60 ml. 0.15 M NaCl 8. Barium Sulfated Beef Plasma. Oxalated beef plasma was adsorbed with mg./ml. barium sulfate and stored in small aliquots at 20C. 9. Substrate Plasma 1 part citrated plasma from a patient severely deficient in Factor IX (stored in small aliquots at 20C.) was mixed with 3 parts barium sulfated beef plasma. 10. Reference Standard Lyophilized plasma reference standard No. 788-27. Assigned potency 0.7 unit per ml.
The cephalin-celite reagent was thoroughly resuspended before use. The substrate reagents were thawed with constant agitation in a water bath at 37C, then mixed in a ratio of one part patients plasma to three parts BaSO beef plasma. It was then kept in a melting ice bath with all other reagents except the calcium solution, which was placed in a 37+C water bath. A standard reference plasma was diluted 1110, 1/50, 1/100, etc., with diluting fluids I and II, according to the method Hjort, et al. [1. Lab. Clin. Med. 46:89-97 (1955)]. Unknowns were tested at suitable dilutions. One-tenth ml. of re-suspended cephalin-celite, 0.1 ml. of substrate plasma, and 0.1 ml. of diluted unknown or standard plasma were transferred to a glass tube in the 37C water bath and a stopwatch started. The mixture was gently tilted during the three minute incubation period to keep the celite in suspension. At the end of three minutes, 0.1 ml. of the CaCl, solution was added and a second stopwatch started. The tube was tilted until clotting occurred. All tests were done in duplicate and the clotting times averaged.
The standard reference plasma was tested with each set of unknowns. A graph was constructed on log-log paper with clotting time on the ordinate and plasma concentrations on the abscissa. The clotting times of the various dilutions of the standard reference plasma were plotted, and the best possible line drawn through the points. The Factor IX concentrations of unknown specimens were determined by reference to this graph. The values obtained for the various concentrations of the unknown were averaged.
In-Vitro Assay of Factor II (Prothrombin) The Factor II assay was a typical Owren One-Stage assay. The results are expressed as units per ml., one unit of prothrombin being defined as that prothrombin activity contained in one ml. of a frozen plasma standard.
In-Vitro Assay of Thromboplastin and Thrombin Thromboplastin and thrombin were estimated simultaneously, by a typical recalcification time test. The clotting time in seconds was compared for the sample and for a control, as follows:
Sample 1 1 ml. citrated plasma 0.1 ml. 0.05 M CaCl, Control 0.1 ml. 0.15 M NaCl 0.1 ml. citrated plasma 0.! ml. 0.05 M CaCl,
The sample was tested at various dilutions with distilled water because high concentrations of neutral electrolyte will inhibit clotting due to any thromboplastin or thrombin.
ASSAY FOR ANTI-COMPLEMENT ACTIVITY The anti-complement assay was done as follows:
1. CF Saline Stock Ca-M g solution g. CaCl,
q.s. 100 ml. with distilled water. 4 g. MgCl,
Add 1 ml. stock solution of 1 liter 0.85% NaCl 2. Alsevers Solution 20.5 g. Dextrose 4.2 g. NaCl 8.0 g. Na Citrate 0.55 g. Citric Acid 3. Sheep Red Blood Cells (S-RBC) Approximately ml. cells were drawn into 40 ml. Alsevers solution. For assay, a portion of cells were washed 3 times with normal saline, then a 2 percent suspension was prepared with CF saline as diluent.
4. l-lemolysin Stock solution 1:100 was prepared using phenol as preservative.
5. Complement Reconstituted as per directions with supplied diluent.
6. Sensitized RBC Warmed 15-30 minutes at 37C before use.
9.5.1 liter with distilled water.
2 units/0.2 ml. vol. Hemolysin 2% S-RBC equal volume Titration l. Hemolysin Doubling dilutions through 1:32 of stock 1:100 solution using CF saline as diluent.
0.2 ml. hemolysin dilutions 0.2 ml. Complement (1:30 with CF saline) 0.2 ml. 2% RBC 0.5 ml. CF saline incubated 30 min. at 37C Highest dilutionof hemolysin giving complete lysis 1 unit. Amount used in assay 2 units/0.2 ml. vol.
Controls (incubated 30 min. at 37C) (1) 1. hemolysin (undiluted) 0.2 in 0.2 ml. 2% RBC 0.7 m
1. CF saline Al'lJControls should e (2) 0.2 ml. complement (1:30) negative (no lysis) 0.2 ml. 2% RBC 0.7 ml. CF saline (3) 0.2 ml. 2% RBC 0.9 ml. CF saline 2. Complement Tube No. l 2 3 4 5 6 7 8 Complement 1:30 ml. .12 .1 l .10 .09 .08 .07 .06 .05 CF saline (ml.) .48 .49 .50 .51 .52 .53 .54 .55
Incubate dilutions 30 min. at 37C Add 0.4 ml. sensitized RBC to each.
0.4 ml. sensitized RBC Incubate 30 min. at 37C Least amount C giving complete lysis unit.
Next highest amount full unit Amount used in assay 2 full units/0.2 ml. vol.
exact Control (incubated 30 min. at 37C) Should be negative 0.6 ml. CF saline (no lysis) Test:
0.2 m1. Sample (doubling dilutions with CF saline as diluent) 0.2 ml. CF saline 0.2 ml. C (2 units) Dilutions were incubated 1 hour at 37C.
0.4 ml. sensitized RBC was added to each.
incubated 30 min. at 37C End point highest dilution sample showing at least 50 percent lysis.
Controls (incubated 30 min. at 37C) 0.2 ml. sample (lowest dilution used) 0.4 ml. sensitized RBC (no lysis) 0.4 ml. CF saline Should be negative (2) 0.2 ml. C (2 units) Should be negative 0.4 ml. sensitized RBC (no lysis) 0.4 ml. CF saline (3) 0.4 ml. sensitized RBC Should be negative 0.6 ml CF saline (no lysis) Depressor Activity The depressor activity was measured by the Depressor Substances Test described in the USP XVll, page 843.
The results obtained by these various techniques are set forth in Table 1.
Expressed as values per vial, or as per unit volume when reconstituted with 20 ml.
-units A batch of coagulation complex of this invention was prepared according to the process described herein. Tests showed the lot to be free of depressor activity, thrombin and thromboplastin, and anticomplement activity. The batch was stored lyophilized at ambient temperature and re-tested 3 months and 6 months later. No depressor activity, thrombin, or thromboplastin were found.
To demonstrate the stability of thecomplex of this invention, a large number of bottles from each of three lots were placed at three different temperature stations and assayed at appropriate intervals. Stability data on lot PR 2240 (1.8 percent moisture), after reconstituting each bottle with 20 ml. water, is presented as an ex- The potency of the complex of this invention was demonstrated by reconstituting a portion of a batch prepared according to the process described herein and assaying it for clotting factors. The results, expressed as 20 percent of normal plasma are shown in Table 111.
TABLE III 11 255096 vn 2400's IX zsooea x 235% (Specific activity of Factor IX: 1.03 units/mg. protein) TABLE v Sample tested Clotting time (secs) Saline (control) 135 Invention sample undiluted 180 Invention sample diluted 1:3 135 Invention sample diluted 1:10 135 CLINICAL RESULTS Human assays have been conducted with the coagulation complex of this invention with patients deficient in Factor IX and with patients deficient in Factor VIl. The coagulation data from ohe of these human assays in a Factor IX deficient patient are presented in Tables VI and VII. During 48 hours subsequent to the administration of the product of this invention containing 2,030 units of Factor IX, there were no abnormalities in blood pressure, pulse, temperature, and respiration. Furthermore, two administrations of the coagulation complex of this invention to the same patient 13 days apart gave no evidence of sensitization or antigenicity.
TABLE VI Dose: 290 m1. (2,030 units) started 11:10 a.m., finished 12:26 p.m.
Elapsed time Clotting factors (percent) Date Time Hours Minutes 11 VII IX X 11:00 a. 0 75 64 1.0 96 12:45 p. 0 20 144 165 54. 2 200 1:10 p. 0 45 136 122 49. 2 1 213 2:20 p. 1 55 123 83 46.0 193 2/ 22/67 3:30 p. 3 5 106 87 44. 5 170 4:25 p. 4 00 105 103 48.6 176 6:30 p. 5 5 110 76 39. 2 185 8:05 p. 7 40 107 75 43. 5 183 10:30 p.m 10 6 106 62 29. 0 183 2:00 a. 13 94 48 24. 3 126 8:35 a. 20 10 100 13. 4 148 2/23/67 11:20 a. 22 56 100 33 13.1 151 2:30 p.111. 26 6 79 34 10. 4 147 4:35 p.m 28 10 101 35 10.8 132 10:05 a.m 40 99 55 9. 1 139 2/24/67 1:00 p.111. 48 35 101 51 9. 6 138 4:30 p.m 52 5 106 58 9. 2 141 2/25/67 10:15 a.m 69 95 37 7.0 117 2/26/67 11:00 am 94 35 92 39 5. 0 121 2/27/67 11:14 a.m 118 60 85 42 3. 35 97 20 2/28/67 2:10 p.m 143 46 80 47 2.9 98
1 Predicted factor IX=56.4%.
The complex of this invention'was tested for and passed all requirements of this USP XVII assay for depressor substances. The results are shown in Table The thromboplastin-thrombin assay above'described gave the following results when a sample of the complex of this invention was tested:
The post-infusion disappearance curve of Factor IX bi-phasic; T k of the first component is 7% hours; T 14 of the second component is 47 hours. The post-infusion half life of the Factor [X in different patients appears to vary from about 20 hours to about 50 hours.
Reliable coagulation assays have b e en collected for the four coagulation components following administration of eight different lots to each of two or more patients. In those patients who would be considered fairly normal (including bleeding patients, but excluding those exhibiting fibrinolysis or widely shifting plasma volumes), the administration of one unit per pound of body weight results in approximately a 4 per cent rise in Factors 11, VII, IX, and X. The post-infusion rise of Factor X is generally a little higher than that of the other three factors.
The product of this invention has been used by 14 clinical investigators in the treatment of emergency CONCENTRATION OF FACTOR IX IN OF NORMAL TA liiliz vI I V V Vd =5X Plasma Vol.
/2: 7-1/2 hrs.
HOURS situations involving over 65 patients. These are patients who had either a permanent congenital deficiency of either Factor VII or IX or X, or who had a temporary acquired deficiency of all four factors (II, VII, IX and X); and who were either highly reactive to plasma or could not tolerate the volume of plasma which would be required; and who were either suffering a serious bleeding episode or who required protection while undergoing major emergency surgery.
The mode of administering the product of this invention will be readily known by physicians. Very generally the lyophilized product is reconstituted with water for injection to make an isotonic solution which is injected intravenously to the patient.
The disclosures and description herein are purely illustrative and are not intended to be in any sense limit-. ing to change that might suggest themselves to those skilled in the art without departing from the spirit and scope of the invention. What is claimed is:
1. A sterile lyophilized storage stable intravenous injectable concentrate of citrated human plasma for controlling bleeding in hemophilia, free of heparin, thrombin, the activated form of Factor X, depressor activity and anticomplement activity, and containing the coagulation Factors II, VII, IX, X in non-activated form, in proportions substantially the same as in human plasma, and having a Factor IX reconstituted potency of at least about 2,000 percent that of normal plasma and a Factor IX specific activity of at least about 0.5 clinical unit per milligram protein and a Factor IX postinfusion biological half-life of about -50 hours.
2. A plasma concentrate according to claim 1 having a Factor IX specific activity of at least about 0.9 clinical units per mg. protein.
3. A mixture of a plasma concentrate according to claim 1 and a NaCl-citrate electrolyte buffer.
4. A process for the production of a storage stable plasma concentrate of the mixture of the Factors II, VII, IX and X coagulation components of human plasma in non-activated form, free of heparin, thrombin, the activated form of Factor X, depressor activity 556 aaiicaifibi'e'm'em activity, which comprises the steps of applying Cohn Supernatant I, Method 6 from unmodified citrated human plasma onto an ion exchange resin consisting essentially of cross-linked dextran chains with diethylaminoethyl groups attached by ether linkages to the glucose units of the polysaccharide chains, and adsorbing thereon said coagulation components of the plasma; selectively eluting the column with ammonium bicarbonate solution of a pH of from about 7.3 to about 8.2 and increasing molarity; separating the eluate fraction containing coagulation components; freezing the separated eluate fraction and removing the ammonium bicarbonate therefrom by lyophilizing the frozen fraction.
5. The process of claim 4 wherein the ammonium bicarbonate solution eluting the fraction containing the coagulation activity is about 0.75 M.
6. The process of claim 4 wherein the resin containing the adsorbed coagulation components is washed free of ceruloplasmin with ammonium bicarbonate solution of up to 0.3 molarity and the coagulation components are eluted with ammonium bicarbonate solution of about 0.75 M until the Factor IX is eluted.
7. The process according to claim 6 wherein the chiate fraction containing coagulation activity is eluted at a pH ofabout 7.6-7.8.
|1||*||Biggs et al., Human Blood Coagulation and its Disorders, 3rd ed., published by Blackwell Scientific Publications, Oxford, 1962, pages 208, 210, 373, & 374|
|2||*||Chemical Abstracts, Vol. 66, entry 9221p, 1967 citing Steinbuch et al., Probl. Gematol. Pereliv. Krovi 11(10), 15 21(1966)|
|3||*||Lewis, Proc. Soc. for Experimental Biology and Medicine, Vol. 116, No. 1, pages 120 122, May 1964|
|4||*||Melin, Studies in the Application of Chromatographic Methods for the Fractionation of the Proteins of Human Plasma, Harvard Univ. April 1964, page 43|
|5||*||Prydz, J. Clin. & Lab. Investigation, Vol. 1, pages 101 107, 1964|
|6||*||Voss, Hoppe Seyler s Z. Physiol. Chem., Vol. 348, pages 1172 1178, Sept. 1967|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US3876775 *||Jun 13, 1973||Apr 8, 1975||Cutter Lab||Stable intravenously injectable plasma protein free from hypotensive effects and process for its production|
|US4081432 *||Jul 25, 1977||Mar 28, 1978||Monsanto Company||Method of separating a Factor IX preparation from plasma using ethylene-maleic anhydride polymers|
|US4093608 *||Apr 1, 1977||Jun 6, 1978||The Green Cross Corporation||Process for purifying coagulation factor VIII using DEAE-crosslinked dextran|
|US4141887 *||May 26, 1977||Feb 27, 1979||Arnold Seufert||Process and apparatus for the production of sterile filtered blood clotting factors|
|US4215109 *||May 17, 1978||Jul 29, 1980||Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.||Medicaments for the suppression of pathological processes|
|US4272521 *||Jul 16, 1979||Jun 9, 1981||Cutter Laboratories, Inc.||Purified immune serum globulin|
|US4361510 *||Feb 2, 1982||Nov 30, 1982||Cutter Laboratories, Inc.||Blood coagulation promoting product|
|US4364861 *||May 27, 1980||Dec 21, 1982||Cutter Laboratories, Inc.||Blood-coagulation-promoting products and methods of preparing them|
|US4370264 *||Sep 8, 1981||Jan 25, 1983||Biotest-Serum-Institut Gmbh||Method for the cold sterilization of preparations containing blood coagulation factor VIII|
|US4391746 *||May 5, 1982||Jul 5, 1983||Cutter Laboratories, Inc.||Blood-coagulation-promoting products and methods of preparing them|
|US4404132 *||Feb 5, 1982||Sep 13, 1983||Cutter Laboratories, Inc.||Blood coagulation promoting product|
|US4459288 *||Mar 22, 1982||Jul 10, 1984||Baxter Travenol Laboratories, Inc.||Therapeutic blood clotting factor compositions and their use|
|US4786726 *||May 22, 1987||Nov 22, 1988||Blood Systems, Inc.||Factor IX therapeutic blood product, means and methods of preparing same|
|US5114916 *||Feb 14, 1990||May 19, 1992||Hoechst Japan Limited||Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants|
|US5621039 *||Jun 8, 1993||Apr 15, 1997||Hallahan; Terrence W.||Factor IX- polymeric conjugates|
|US6670455||Aug 4, 2000||Dec 30, 2003||Aventis Behring Gmbh||Process for the preparation in pure form of the protease activating blood clotting VII, its proenzyme or a mixture of both proteins by means of affinity chromatography|
|US20040063187 *||Oct 1, 2003||Apr 1, 2004||Aventis Behring Gmbh||Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or a mixture of both proteins by means of chromatography|
|DE3025078A1 *||Jul 2, 1980||Feb 5, 1981||Cutter Lab||Gereinigtes immunserumglobulin- praeparat|
|EP0000651A1 *||Jul 21, 1978||Feb 7, 1979||Monsanto Company||Method of separating a factor IX preparation from blood plasma|
|EP0044343A1 *||Jan 2, 1981||Jan 27, 1982||Baxter Travenol Lab||Prothrombin-containing therapeutic compositions and methods of producing enzymatically active blood clotting factors from prothrombin-containing blood fractions.|
|EP0636319A2 *||Jul 8, 1994||Feb 1, 1995||Pall Corporation||Method of filtering a protein-containing fluid|
|EP1074615A1 *||Jul 5, 2000||Feb 7, 2001||Aventis Behring GmbH||Methods for purification of Factor VII activating Protease, its proenzyme or a mixture of both forms, by affinity chromatography|
|WO2007053533A2 *||Oct 27, 2006||May 10, 2007||Wyeth Corp||Sodium chloride solution for drug reconstitution or dilution|
|U.S. Classification||530/384, 530/831, 514/802|
|International Classification||A61K38/00, C12N9/74|
|Cooperative Classification||C12N9/6429, A61K38/00, Y10S530/831, Y10S514/802, C12Y304/21005|